Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Catalytic antibodies and a method of producing same

a catalytic antibody and antibody technology, applied in the field of growth factor precursors, can solve the problems of difficult to predict the structure of transition state analogs, ineffective recombinant techniques in generating all components of humoral responses, and inefficient immunisation of mice with transition state analogs

Inactive Publication Date: 2009-10-29
KOENTGEN FRANK
View PDF8 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0013]One aspect of the present invention is directed to a growth factor precursor comprising a recombinant polypeptide chain or a molecule having modular peptide components or a synthetic equivalent thereof wherein said polypeptide chain or modular peptide molecule comprises at least one B cell surface molecule binding portion, at least one T cell surface molecule binding portion capable of providing T cell dependent help to a B cell, an antigen cleavable by a catalytic antibody and a peptide portion comprising domains from both a variable heavy chain and a variable light chain of an immunoglobulin and wherein said variable heavy chain and variable light chain domains in the growth factor precursor, associate together by intra- and / or inter-domain bonding and substantially prevent the at least one B cell surface molecule binding portion from interacting with a B cell surface molecule such that upon cleavage of said antigen by a catalytic antibody, the peptide comprising said variable heavy chain and variable light chain domain permits the at least one B cell surface molecule binding portion to interact with a B cell surface molecule.
[0015]Yet another aspect of the present invention provides a growth factor precursor comprising a recombinant polypeptide chain or a molecule having modular peptide components or a synthetic equivalent thereof wherein said polypeptide chain or modular peptide molecule comprises at least two B cell surface molecule binding portions, at least one T cell surface molecule binding portion capable of providing T cell dependent help to a B cell, an antigen cleavable by a catalytic antibody and a peptide portion comprising domains from both a variable heavy chain and a variable light chain such that in the growth factor precursor, these variable chain domains associate together by intra- and / or inter-domain bonding and, when associated together, substantially prevent at least one of the B cell surface molecule binding portions from interacting with a B cell surface molecule wherein upon cleavage of said antigen by a catalytic antibody, the at least two B cell surface molecule binding portions induce activation and proliferation of a B cell expressing said catalytic antibody.

Problems solved by technology

However, recombinant techniques have not been fully effective in generating all components of the humoral response.
However, this approach has a severe limitation in that it is difficult to predict the structure of transition state analogs which effect proteolysis of specific proteins.
Immunising a mouse with a transition state analog is by definition inefficient since it selects B cells on the ability of surface immunoglobulins to bind the analogs and not on the ability of a surface immunoglobulins to catalytically cleave the analogue.
However, to date, such an approach has not proved successful.
As a consequence, catalytic antibodies have not previously achieved prominence as therapeutic, diagnostic or industrial tools.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Catalytic antibodies and a method of producing same
  • Catalytic antibodies and a method of producing same
  • Catalytic antibodies and a method of producing same

Examples

Experimental program
Comparison scheme
Effect test

example 1

Generation of LHL from Synthetic Oligonucleotides

[0152]LHL was generated from three overlapping synthetic oligos, a 115mer, a 116mer and a 105mer, using the proofreading DNA polymerase Pfu in two 20 cycle PCR reactions. The two PCR products (290 bp and 200 bp) were purified and blunt end cloned into the expression vector pASK75. The sequence was verified by automated sequencing. All subsequent PCRs were done in a similar fashion as described in the literature. The nucleotide and corresponding amino acid sequence for LHL is shown in SEQ ID NO: 1 and SEQ ID NO:2 respectively.

example 2

Expression of LHL in E. coli and Purification Over a Human IgG (huIgG) Affinity Column

[0153]The expression vector pASK75 directs protein expression via the ompA signal peptide into the periplasm of E. coli. Protein expression was induced with 200 ng / ml anhydrotetracycline for 16 hrs in midlog E. coli DH10B cultures. Cells were lysed and soluble LHL purified (>95%) over a huIgG affinity column. Extensive washes with 0.5% v / v Triton X-100 were performed on the affinity column in order to eliminate endotoxins from the preparations. Expression levels were estimated at 200 mg per litre of culture.

example 3

Generation of an LHL Protein Carrying the N-Terminal Flag Epitope and the C-Terminal Strep-Tag

[0154]A form of LHL (referred to herein as “LHL.seq”) was generated by PCR containing the FLAG epitope at its N-terminus and the so called strep-tag at its C-terminus. The nucleotide and corresponding amino acid sequence for LHL.seq is shown in SEQ ID NO:7 and SEQ ID NO:8, respectively. The FLAG epitope comprises the amino acids DYKDDDDK (SEQ ID NO:9) and the strep-tag the amino acids AWRHPQFGG (SEQ ID NO: 14). The FLAG epitope is recognised by several anti-FLAG monoclonal antibodies and the strep-tag by streptavidin. The strep-tag was used for purification of LHL.seq over a streptavidin column. LHL.seq was washed with 0.5% v / v Triton X-100, Tween20 and PBS while bound to the column in order to minimise endotoxin levels. LHL.seq was eluted with either 100 mM glycine pH2.0 or with 1 mg / ml diaminobiotin in PBS. In this method LHL.seq was not purified on the basis of binding immunoglobulin, th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Magnetic fieldaaaaaaaaaa
Digital informationaaaaaaaaaa
Login to View More

Abstract

The present invention relates generally to a growth factor precursor and its use to select production of antigen specific catalytic antibodies. Such catalytic antibodies are produced following B cell activation and proliferation induced by catalytic cleavage products of a target antigen portion of the growth factor precursor of the present invention. A particularly useful form of the growth factor precursor is as a nucleic acid vaccine. The nucleic acid vaccine of the present invention preferably further comprises a molecular adjuvant. Another aspect of the present invention comprises a growth factor precursor in multimeric form. The growth factor precursor of the present invention is useful for generating catalytic antibodies for both therapeutic, diagnostic and industrial purposes.

Description

FIELD OF THE INVENTION[0001]The present invention relates generally to a growth factor precursor and its use to select production of antigen specific catalytic antibodies. Such catalytic antibodies are produced following B cell activation and proliferation induced by catalytic cleavage products of a target antigen portion of the growth factor precursor of the present invention. A particularly useful form of the growth factor precursor is as a nucleic acid vaccine. The nucleic acid vaccine of the present invention preferably further comprises a molecular adjuvant. Another aspect of the present invention comprises a growth factor precursor in multimeric form. The growth factor precursor of the present invention is useful for generating catalytic antibodies for both therapeutic, diagnostic and industrial purposes.BACKGROUND OF THE INVENTION[0002]The rapidly increasing sophistication of recombinant DNA technology is greatly facilitating research and development in the medical and allied...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395C12N9/00C07H21/00A61K39/44C07K16/18C12N15/19
CPCC07K16/18C07K2317/622C12N9/0002C07K2319/00C07K2317/624
Inventor KOENTGEN, FRANKSUESS, GABRIELE MARIATARLINTON, DAVID MATHEWTREUTLEIN, HERBERT RUDOLF
Owner KOENTGEN FRANK
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com